Nuwellis Inc. to Participate at the 2021 Ladenburg Thalmann Healthcare Conference

Rhea-AI Summary

Nuwellis, Inc. (NASDAQ: NUWE) announced participation in the 2021 Ladenburg Thalmann Healthcare Conference, scheduled for July 14, 2021, at 4:00 pm ET. The event will include a presentation and a fireside chat featuring CEO Nestor Jaramillo and CFO George Montague. An audio webcast will be accessible through Nuwellis’ investor relations website, with a replay available for 90 days post-event. Nuwellis focuses on treating fluid overload through its Aquadex SmartFlow system, which is designed for both adult and pediatric patients when diuretics are ineffective.

EDEN PRAIRIE, Minn., July 06, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), a company focused on providing solutions for patients suffering from fluid overload, today announced that, Nestor Jaramillo, Chief Executive officer, and George Montague, Chief Financial Officer, are scheduled to participate in the 2021 Ladenburg Thalmann Healthcare Conference on Wednesday, July 14^th, 2021.

Event:	2021 Ladenburg Thalmann Healthcare Conference
Format:	Presentation & Fireside Chat
Date:	Wednesday, July 14, 2021
Time:	4:00 pm ET

An audio webcast of the presentation will be available online at the Nuwellis’ investor relations website, https://ir.nuwellis.com. Additionally, a replay will be available for 90 days after the presentation.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing, and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is a Delaware corporation headquartered in Minneapolis, Minnesota with a wholly owned subsidiary in Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

CONTACTS

INVESTORS:
Matt Basco, CFA
Gilmartin Group LLC
Matt.bacso@gilmartinir.com

MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com

FAQ

What is the date of the Nuwellis participation at the 2021 Ladenburg Thalmann Healthcare Conference?

Nuwellis is scheduled to participate in the conference on July 14, 2021.

Who will represent Nuwellis at the 2021 Ladenburg Thalmann Healthcare Conference?

Nestor Jaramillo, CEO, and George Montague, CFO, will represent Nuwellis.

What time is the Nuwellis presentation at the Ladenburg Thalmann Healthcare Conference?

The Nuwellis presentation is scheduled for 4:00 pm ET.

Where can I listen to the Nuwellis presentation at the conference?

The presentation will be available via audio webcast on Nuwellis’ investor relations website.

How long will the replay of the Nuwellis conference presentation be available?

A replay of the presentation will be available for 90 days after the event.

What is the focus of Nuwellis as a company?

Nuwellis focuses on providing solutions for patients suffering from fluid overload.

What product does Nuwellis offer for fluid overload?

Nuwellis offers the Aquadex SmartFlow system for ultrafiltration therapy.